Owing to its enhanced transport across the BBB, an anti-TfR monoclonal antibody-EPO conjugate intravenously injected into mouse stroke models dramatically reduced the hemispheric stroke volume compared to its antibody-free counterpart [95]. This evidence concerns the gene TFRC and stroke disorder.